Cefuroxime (free base) | CAS# 55268-75-2 (free base) | cephalosporin antibiotic

MedKoo Cat#: 412546 | Name: Cefuroxime (free base)

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cefuroxime (free base) is a broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, GONORRHEA, and HAEMOPHILUS.

Chemical Structure

Cefuroxime (free base)

CAS#55268-75-2 (free base)

Theoretical Analysis

MedKoo Cat#: 412546

Name: Cefuroxime (free base)

CAS#: 55268-75-2 (free base)

Chemical Formula: C16H16N4O8S

Exact Mass: 424.0689

Molecular Weight: 424.38

Elemental Analysis: C, 45.28; H, 3.80; N, 13.20; O, 30.16; S, 7.55

Price and Availability

Size	Price	Availability
500mg	USD 350.00	2 weeks
1g	USD 550.00	2 weeks
2g	USD 950.00	2 Weeks
5g	USD 1,650.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

56238-63-2 (sodium) 55268-75-2 (free base) 64544-07-6 (axetil) 100680-33-9 (pivoxetil)

Synonym

Cefuroxime (free base); Cefuril; Sharox; BRN5783190; BRN-5783190; BRN 5783190

IUPAC/Chemical Name

5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((aminocarbonyl)oxy)methyl)-7-((2-furanyl(methoxyimino)acetyl)amino)-8-oxo-, (6R-(6alpha,7beta(Z)))-

InChi Key

JFPVXVDWJQMJEE-IZRZKJBUSA-N

InChi Code

InChI=1S/C16H16N4O8S/c1-26-19-9(8-3-2-4-27-8)12(21)18-10-13(22)20-11(15(23)24)7(5-28-16(17)25)6-29-14(10)20/h2-4,10,14H,5-6H2,1H3,(H2,17,25)(H,18,21)(H,23,24)/b19-9-/t10-,14-/m1/s1

SMILES Code

O=C(C(N12)=C(COC(N)=O)CS[C@]2([H])[C@H](NC(/C(C3=CC=CO3)=N\OC)=O)C1=O)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 424.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Steere AC, Strle F, Wormser GP, Hu LT, Branda JA, Hovius JW, Li X, Mead PS. Lyme borreliosis. Nat Rev Dis Primers. 2016 Dec 15;2:16090. doi: 10.1038/nrdp.2016.90. Review. Erratum in: Nat Rev Dis Primers. 2017 Aug 03;3:17062. PubMed PMID: 27976670; PubMed Central PMCID: PMC5539539. 2: Dalal N, Buckner IS, Wildfong PLD. Experimental Determination and Theoretical Calculation of the Eutectic Composition of Cefuroxime Axetil Diastereomers. AAPS PharmSciTech. 2017 Oct;18(7):2570-2578. doi: 10.1208/s12249-017-0739-8. Epub 2017 Feb 22. PubMed PMID: 28229357. 3: Pakes GE, Graham JA, Rauch AM, Collins JJ. Cefuroxime axetil in the treatment of sinusitis. A review. Arch Fam Med. 1994 Feb;3(2):165-75. Review. PubMed PMID: 7994439. 4: Jammula S, Patra ChN, Swain S, Panigrahi KC, Nayak S, Dinda SC, Rao ME. Design and characterization of cefuroxime axetil biphasic floating minitablets. Drug Deliv. 2015 Jan;22(1):125-35. doi: 10.3109/10717544.2013.871603. Epub 2014 Jan 13. PubMed PMID: 24417642. 5: Dellamonica P. Cefuroxime axetil. Int J Antimicrob Agents. 1994 Mar;4(1):23-36. PubMed PMID: 18611587. 6: File TM Jr, Segreti J, Dunbar L, Player R, Kohler R, Williams RR, Kojak C, Rubin A. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother. 1997 Sep;41(9):1965-72. PubMed PMID: 9303395; PubMed Central PMCID: PMC164046. 7: Marx MA, Fant WK. Cefuroxime axetil. Drug Intell Clin Pharm. 1988 Sep;22(9):651-8. Review. PubMed PMID: 3063476. 8: Talaczyńska A, Lewandowska K, Jelińska A, Garbacki P, Podborska A, Zalewski P, Oszczapowicz I, Sikora A, Kozak M, Cielecka-Piontek J. Application of vibrational spectroscopy supported by theoretical calculations in identification of amorphous and crystalline forms of cefuroxime axetil. ScientificWorldJournal. 2015;2015:921049. doi: 10.1155/2015/921049. Epub 2015 Jan 11. PubMed PMID: 25654137; PubMed Central PMCID: PMC4306215. 9: Jelińska A, Dudzińska I, Zajac M, Oszczapowicz I, Krzewski W. The stability of Cefuroxime axetil in tablets. Acta Pol Pharm. 2005 May-Jun;62(3):183-7. PubMed PMID: 16193810. 10: Garbacki P, Teżyk A, Zalewski P, Jelińska A, Paczkowska M, Talczyńska A, Oszczapowicz I, Cielecka-Piontek J. Assay of Diastereoisomers of Cefuroxime Axetil in Amorphous and Crystalline Forms Using UHPLC-DAD. Chromatographia. 2014;77(21-22):1489-1495. Epub 2014 Oct 9. PubMed PMID: 25400288; PubMed Central PMCID: PMC4224750. 11: Ruiz-Balaguer N, Nacher A, Casabo VG, Merino M. Nonlinear intestinal absorption kinetics of cefuroxime axetil in rats. Antimicrob Agents Chemother. 1997 Feb;41(2):445-8. PubMed PMID: 9021205; PubMed Central PMCID: PMC163727. 12: Akman C, Duran A, Kalafat UM, Ocak T. Uveitis attack and drug reaction due to cefuroxime axetil. Cutan Ocul Toxicol. 2016 Sep;35(3):254-6. doi: 10.3109/15569527.2015.1067817. Epub 2015 Jul 23. PubMed PMID: 26203731. 13: Singh B, Vuddanda PR, M R V, Kumar V, Saxena PS, Singh S. Cefuroxime axetil loaded solid lipid nanoparticles for enhanced activity against S. aureus biofilm. Colloids Surf B Biointerfaces. 2014 Sep 1;121:92-8. doi: 10.1016/j.colsurfb.2014.03.046. Epub 2014 Apr 18. PubMed PMID: 24945607. 14: Sanchez E, Vannier E, Wormser GP, Hu LT. Diagnosis, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: A Review. JAMA. 2016 Apr 26;315(16):1767-77. doi: 10.1001/jama.2016.2884. Review. PubMed PMID: 27115378. 15: Nagar M, Yadav AV. Chitosan-based intragastric delivery of cefuroxime axetil: development and in-vitro evaluation of mucoadhesive approach. Artif Cells Blood Substit Immobil Biotechnol. 2012 Dec;40(6):406-18. doi: 10.3109/10731199.2012.696064. Epub 2012 Jul 10. PubMed PMID: 22780098. 16: Del Villar-Guerra P, Moreno Vicente-Arche B, Castrillo Bustamante S, Santana Rodríguez C. Anaphylactic reaction due to cefuroxime axetil: A rare cause of anaphylaxis. Int J Immunopathol Pharmacol. 2016 Dec;29(4):731-733. Epub 2016 Aug 16. PubMed PMID: 27531605; PubMed Central PMCID: PMC5806846. 17: Velioglu A, Asicioglu E, Ari E, Arikan H, Tuglular S, Ozener C. Prevention of peritonitis in newly-placed peritoneal dialysis catheters: efficacy of oral prophylaxis with cefuroxime axetil - a preliminary study. Minerva Urol Nefrol. 2016 Feb;68(1):27-31. Epub 2015 Feb 12. PubMed PMID: 25675290. 18: Ruiz-Carretero P, Merino-Sanjuán M, Nácher A, Casabó VG. Pharmacokinetic models for the saturable absorption of cefuroxime axetil and saturable elimination of cefuroxime. Eur J Pharm Sci. 2004 Feb;21(2-3):217-23. PubMed PMID: 14757493. 19: Uzunović A, Vranić E. Stability of cefuroxime axetil oral suspension at different temperature storage conditions. Bosn J Basic Med Sci. 2008 Feb;8(1):93-7. PubMed PMID: 18318680; PubMed Central PMCID: PMC5724884. 20: Israr F, Mahmood ZA, Hassan F, Hasan SM. Pharmaceutical Evaluation of Cefuroxime Axetil Tablets Available in Drug Market of Pakistan. Indian J Pharm Sci. 2016 Jan-Feb;78(1):17-26. PubMed PMID: 27168677; PubMed Central PMCID: PMC4852570.